000			02201 a2200613 4500
005			20250516080452.0
264		0	_c20120629
008			201206s 0 0 eng d
022			_a1791-2423
024	7		_a10.3892/ijo.2012.1368 _2doi
040			_aNLM _beng _cNLM
100	1		_aTakeuchi, Ario
245	0	0	_aSunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation. _h[electronic resource]
260			_bInternational journal of oncology _cMay 2012
300			_a1691-6 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Agents _xpharmacology
650	0	4	_aBlotting, Western
650	0	4	_aCell Line, Tumor
650	0	4	_aCell Proliferation _xdrug effects
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDown-Regulation
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aIndoles _xpharmacology
650	0	4	_aLymphocytes, Tumor-Infiltrating _xdrug effects
650	0	4	_aMice
650	0	4	_aMice, Inbred C3H
650	0	4	_aMice, Nude
650	0	4	_aMitogen-Activated Protein Kinase 1 _xantagonists & inhibitors
650	0	4	_aMitogen-Activated Protein Kinase 3 _xantagonists & inhibitors
650	0	4	_aPhosphorylation
650	0	4	_aProtein Kinase Inhibitors _xpharmacology
650	0	4	_aPyrroles _xpharmacology
650	0	4	_aSignal Transduction _xdrug effects
650	0	4	_aSunitinib
650	0	4	_aT-Lymphocytes, Cytotoxic _xdrug effects
650	0	4	_aT-Lymphocytes, Regulatory _xdrug effects
650	0	4	_aTime Factors
650	0	4	_aTumor Burden _xdrug effects
650	0	4	_aUrinary Bladder Neoplasms _xdrug therapy
650	0	4	_aXenograft Model Antitumor Assays
700	1		_aEto, Masatoshi
700	1		_aShiota, Masaki
700	1		_aTatsugami, Katsunori
700	1		_aYokomizo, Akira
700	1		_aKuroiwa, Kentaro
700	1		_aItsumi, Momoe
700	1		_aNaito, Seiji
773	0		_tInternational journal of oncology _gvol. 40 _gno. 5 _gp. 1691-6
856	4	0	_uhttps://doi.org/10.3892/ijo.2012.1368 _zAvailable from publisher's website
999			_c21554842 _d21554842